NOT CONSIDERED

ALTERNATIVE TO PTO/SB/08A/B (09/06)

INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

09/809,638 March 14, 2001 Filing Date First Named Inventor Mary FARIS Art Unit 1643

Complete if Known

(Use as many sheets as necessary)

Sheet 1 of 1

for form 1449/PTO

A. Harris **Examiner Name** 511582003500 Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ² (If known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear

Application Number

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۲°
			1		•	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sental number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, pragazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	CHEN, Current Opinion in Immunology (1999) 11(2):219-222	
	2.	Database UniProt, accession no. Q9H720 (March 2001)	
	3.	Supplementary Partial European Search Report for EP 02726630.3, mailed on 10 January 2007, 4 pages	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

NOT CONSIDERED	any 05/18/2007
Examiner Signature	Date Considered
sd- 361558	

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 847895312 US, on the date shown below in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Bated: March 2, 2007

Patent Docket No. 511582003500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: lary FARIS et al.

Serial No.: 09/809,638

Filing Date: March 14, 2001

125P5C8: A TISSUE SPECIFIC

PROTEIN HIGHLY EXPRESSED IN

VARIOUS CANCERS

Examiner: A. Harris

Group Art Unit: 1643

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO/SB/08a/b were cited in a Supplementary Partial European Search Report mailed on January 10, 2007, directed to a counterpart international or foreign application and have not been previously cited. A certification under 37 C.F.R. § 1.97(e)(1) follows:

03/12/2007 HGUTEMA1 00000019 031952 09809638 01 FC:1806 180.00 DA

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1)	has been provided.
	Withi	n three months of the application filing date or before mailing of a first Office Action
	on the	e merits; accordingly, no fee or separate requirements are required. However, if
	applic	cable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or No	tice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
\boxtimes	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 511582003500.

Dated: March 2, 2007

Respectfully submitted,

James J. Mullen, III

Registration No.: 44,957

MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

(858) 720-7940